Cargando…
A sensitive and reproducible cell-based assay via secNanoLuc to detect neutralizing antibody against adeno-associated virus vector capsid
Most gene therapy clinical trials that systemically administered adeno-associated virus (AAV) vector enrolled only patients without anti-AAV-neutralizing antibodies. However, laboratory tests to measure neutralizing antibodies varied among clinical trials and have not been standardized. In this stud...
Autores principales: | Baatartsogt, Nemekhbayar, Kashiwakura, Yuji, Hayakawa, Morisada, Kamoshita, Nobuhiko, Hiramoto, Takafumi, Mizukami, Hiroaki, Ohmori, Tsukasa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397836/ https://www.ncbi.nlm.nih.gov/pubmed/34485602 http://dx.doi.org/10.1016/j.omtm.2021.06.004 |
Ejemplares similares
-
Genome editing of patient-derived iPSCs identifies a deep intronic variant causing aberrant splicing in hemophilia A
por: Hiramoto, Takafumi, et al.
Publicado: (2023) -
PAM-flexible Cas9-mediated base editing of a hemophilia B mutation in induced pluripotent stem cells
por: Hiramoto, Takafumi, et al.
Publicado: (2023) -
The seroprevalence of neutralizing antibodies against the adeno-associated virus capsids in Japanese hemophiliacs
por: Kashiwakura, Yuji, et al.
Publicado: (2022) -
Characterization and visualization of murine coagulation factor VIII-producing cells in vivo
por: Hayakawa, Morisada, et al.
Publicado: (2021) -
Efficient gene transduction in pigs and macaques with the engineered AAV vector AAV.GT5 for hemophilia B gene therapy
por: Kashiwakura, Yuji, et al.
Publicado: (2023)